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Summary: 47 
Research on the peripheral effects of COPD has focused on physiological and structural changes. 48 
However, different from muscular weakness or decreased physical activity, mechanical 49 
abnormalities of the muscular system, e.g. walking, have yet to be investigated. Our purpose was 50 
to utilize the National Health and Nutritional Examination Survey (NHANES) dataset to 51 
determine whether walking abnormalities are associated with COPD severity. To determine if 52 
walking abnormalities were independently associated with COPD severity, our analysis aimed to 53 
investigate the association of physical activity levels with COPD severity and with walking 54 
abnormalities. The NHANES III dataset that contains data for 31,000 persons that were collected 55 
from 1988-1994, was used to explore the association of COPD severity on gross walking 56 
abnormalities, i.e. limp, shuffle, etc. Logistic regression models were created using FEV1/FVC 57 
ratio, age, gender, BMI, and smoking status as predictors of walking abnormalities and physical 58 
activity in persons aged 40 to 90 years old. Results demonstrated a significant correlation 59 
between the presence of walking abnormalities and severe COPD (odds ratio: 1.97; 95% CI: 1.1 60 
to 3.5). This suggests that disease severity can contribute to mechanical outcomes of patients 61 
with COPD. In addition, decreased physical activity levels were significantly associated with all 62 
COPD severity levels with the exception of mild COPD. The association between altered gait 63 
and COPD status may be due to the presence of physical inactivity that is present in patients with 64 
COPD. Future research directions should include investigating more closely the mechanical 65 
outcomes of persons with COPD. 66 
 67 
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Introduction: 86 
The effects of COPD are not limited to the lungs; rather the effects typically include “systemic 87 
and complex abnormalities” affecting the peripheral systems 1. At the forefront of these are the 88 
effects of COPD on the cardiovascular and muscular systems. Much of the research into the 89 
effects of COPD on the muscular system has focused on skeletal muscle changes, including 90 
muscle atrophy, mitochondrial changes and shifting of muscle fiber types 2-5. It is possible then 91 
that changes in muscular structure could affect mechanical outcomes, such as gait (walking). 92 
However, this has not been explored in the COPD population.  93 
 94 
COPD patients are less active than the average population 6-9. Using accelerometers to 95 
objectively quantify physical activity 10-13, it is reported that one third of severe COPD patients 96 
walk less than 15 min/day 8. Patients with the most severe levels of COPD spend less time 97 
walking and when they do, they walk at slower speeds 14. The decreased physical activity seen in 98 
COPD patients is not directly associated with disease severity. Mild COPD patients, that have 99 
relatively normal lung function, walk approximately 50% less than healthy controls 7. Watz et al. 100 
(2009) have further demonstrated that patients with moderate COPD have significantly 101 
decreased physical activity levels and that these decremented physical activity levels are not 102 
reflective of clinical tests of disease severity 15. Physical inactivity in COPD patients is the result 103 
of many abnormalities, including the ventilatory, musculoskeletal, neurosensory, and 104 
cardiovascular systems. Respiratory limits to physical activity are well established 16-18. Including 105 
dynamic hyperinflation that worsens with activity, can impact activity levels by constraining 106 
tidal volume, contributing to inspiratory muscle weakness, greater neuromechanical dissociation, 107 
and increased perception of dyspnea regardless of the level of severity of COPD 16-18. In addition, 108 
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it has been noted that dynamic hyperinflation contributes to a circle of increased weakness and 109 
fatigue of respiratory musculature; hence, causing a further impact physical activity levels 17. 110 
Additional extrapulmonary effects of COPD include an association of physical inactivity with 111 
systemic inflammation and impaired left cardiac function, as well as an increased prevalence of 112 
peripheral arterial disease and depression 19. 113 
 114 
There is evidence that lack of physical activity contributes to peripheral muscle abnormalities 115 
and dysfunction. Disuse of the muscular system can result in muscular atrophy, decreased 116 
muscle strength, increased muscle fatigability, reduced oxidative capacity, and capillary loss 20-23. 117 
It has also been reported that activity may be limited in COPD patients due to leg fatigue 24. 118 
Muscle fatigue is present in mild to moderate COPD patients irrespective to lung function, 119 
anthropometric data, or quadriceps strength 25. A contributing factor to leg fatigue could be 120 
abnormal skeletal muscle structure, including abnormal body cell mass alterations, muscular 121 
protein degradation leading to muscle wasting/atrophy, impaired energy production and 122 
metabolic performance, and increased susceptibility to muscle weakness 2, 26-33.  These muscular 123 
impairments may also lead to abnormal walking patterns; however this has not previously been 124 
tested in COPD patients. In support of such a concept, however, Butcher et al. (2004) 125 
investigated balance, coordination and mobility in COPD patients and determined that 126 
decrements in these measures were found when compared to controls 34. These differences were 127 
attributed to severity of disease and lower levels of physical activity 34. Whatever the cause, 128 
mechanical abnormalities are present in COPD patients.  Using biomechanical measures to 129 
quantify static balance control in COPD, it has been found that COPD patients demonstrate 130 
greater medio-lateral center of pressure displacement and increased hip angular displacement of 131 
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the hip 35.  Whether these are reflected in walking abnormalities remains to be determined.  132 
Interestingly, patients with COPD also demonstrate an increase risk of falls as compared to 133 
healthy controls, with a reported odds ratio of 4 to 5 times higher 36, 37. Roig et al. (2009) propose 134 
a theoretical framework to identify fall risk factors in COPD patients which includes walking 135 
abnormalities leading to poor mobility 38. Hence, there is a demonstrated need to investigate 136 
mechanical outcomes in COPD, including but not limited to, walking abnormalities and balance 137 
measures.  138 
 139 
The purpose of this study was to investigate whether or not walking abnormalities are associated 140 
with the presence of COPD using data from the NHANES III dataset. The National Health and 141 
Nutritional Examination Survey (NHANES) III dataset is a public use data set that provides 142 
interview and physical examination information on over 31,000 American patients from 1988 to 143 
1994. NHANES is a major program of the United States National Center for Health Statistics 144 
that is regulated by Centers for Disease Control and Prevention. This dataset provides 145 
information regarding mechanical outcomes of patients as well as history, physical examination 146 
and laboratory measures, including information on the prevalence of chronic diseases. 147 
Using this dataset, we hypothesized that walking abnormalities would be significantly associated 148 
with COPD severity, due to the prevalence of peripheral muscle abnormalities and dysfunction 149 
noted in COPD. It is thought that these peripheral muscle changes are due to the severe physical 150 
inactivity commonly present in patients with COPD. Therefore, a secondary analysis conducted 151 
investigating the association of subjective physical activity levels with COPD severity. It was 152 
hypothesized that all levels of COPD severity would be significantly associated with decreased 153 
physical activity levels, providing further support that physical inactivity associated with COPD 154 
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is related to walking abnormalities. The relationship between COPD severity and activity level is 155 
neither novel nor unexpected; however the goal was to determine if activity level was related to 156 
walking abnormality and which variables are independently associated with abnormal walking 157 
patterns. 158 
 159 
Methods and Materials: 160 
Data from the NHANES III dataset were used for analysis. Extensive details of the sampling and 161 
data collection methodologies are available at 162 
www.cdc.gov/nchs/about/major/nhanes/nh3data.htm. In order to account for the sampling design 163 
that produced the NHANES dataset, all modeling analyses and descriptive analyses where 164 
weights are taken into account were performed using SAS SURVEY procedures with appropriate 165 
stratification, clustering, and weighting variables (SAS Institute Inc., Cary, NC). These analyses 166 
utilized data from the full six year sample as recommended by the study documentation. These 167 
analyses were approved as exempt by the University’s Institutional Review Board. 168 
 169 
Selection Criteria: The original NHANES III dataset contains data on 31,311 Americans 170 
examined and surveyed from 1988-1994. Patients that had completed the adult examination and 171 
were 40 to 90 years old were selected for analysis (n = 10,049). From this selected group, 172 
subjects were eliminated from analyses if they reported being unable to walk without help (n = 173 
240). This variable is included in the physical function evaluation given to anyone over the age 174 
of 60 years. Persons who were coded as “no” they could not walk without help were removed 175 
from the analyses. Finally, potential subjects were removed if they were missing data from one 176 
of the key variables for analyses (FEV1, FVC, walking abnormalities, age, gender, body mass 177 
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index (BMI) (n = 1,404)). In total, 8,405 patient records were utilized as a sample for this 178 
analysis. 179 
 180 
Selection of Variables: The independent variable chosen for this analysis was classification of 181 
COPD status. Spirometric function was used for the definition of COPD.  The key parameters 182 
were the patient’s forced expiratory volume in one second (FEV1) and the ratio of the FEV1 to 183 
the forced vital capacity (FVC) 39. Patients with an FEV1 to FVC ratio less than 0.7 were 184 
classified as having COPD with severity stages determined by classification based on their 185 
measured FEV1 values as a percent of their predicted FEV1 values.  The percent predicted FEV1 186 
values were calculated using equations derived by Harkinson et al. 40 for the NHANES III dataset 187 
which calculate predicted values for each subject based on the subject’s age, height, race, and 188 
gender. Utilizing standards from The Global Initiative for Chronic Obstructive Pulmonary 189 
Disease (GOLD), subjects were classified into three COPD levels 41 as well as symptoms, 190 
restrictive, and normal classification groups (Table 1) 42.   191 
 192 
Two separate models were developed. The first model was developed to investigate the presence 193 
of walking abnormalities in persons with COPD, using the presence of gait abnormality as a 194 
dependent variable. Three variables in the NHANES III dataset address walking abnormalities. 195 
The protocol for NHANES states that the physician should evaluate the patient for a limp or 196 
shuffle (variable PEP1A1). According to the NHANES instructions this must be a chronic limp 197 
on either leg that is a current condition. If a limp or shuffle were not present, the physician could 198 
additionally evaluate the patient for any other walking abnormality (variable PEP1A2). If the 199 
physician marked “yes” to either of these conditions, the overall finding for walking 200 
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abnormalities was marked as “yes” (variable PEP1). Only the overall finding for the locomotion 201 
variable was used for analysis. This variable was coded as “yes, findings” if either one or both of 202 
the other two variables (limp or shuffle and/or other walking abnormalities) were coded as “yes”.  203 
The second model was developed to investigate the association of physical activity levels with 204 
COPD status. The dependent variable for this model was a subjective measure of physical 205 
activity. In the NHANES III Adult Household Survey, physical activity was assessed using the 206 
following variable, “How active are you compared with men/women your age?” (variable 207 
HAT28) In the NHANES data set, the data was coded as: more active, less active, about the 208 
same, blank but applicable, and don't know. 209 
 210 
Age, gender, and BMI were chosen as covariates. Descriptive statistics for all analysis variables 211 
are presented in Table 2. In addition to the covariates, smoking status was added to the analysis. 212 
Data from the NHANES III Adult Household Survey was used to create the smoking status 213 
variable.  A person was classified as “never” smoking if he/she reported smoking fewer than all 214 
of 100 cigarettes, 20 cigars, or 20 pipefuls of tobacco in his/her lifetime. Among persons who 215 
had smoked at least 100 cigarettes, 20 cigars, or 20 pipefuls of tobacco, those who reported they 216 
were not currently smoking any of cigarettes, pipes, or cigars were classified as “former” 217 
smokers, while those who indicated they were currently using at least one of these three options 218 
were classified as “current” smokers.  219 
 220 
Model Development: The SAS SURVEYLOGISTIC procedure was used to generate logistic 221 
regression models with gait abnormality and physical activity as dependent variables and COPD 222 
classification as the independent variable.  Age, BMI, gender, and smoking status were added to 223 
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the model to control for their effects on the outcome variable. Significance was set at an alpha 224 
level of 0.05.  For the physical activity model, responses of “More active” and “About the same” 225 
were combined into a single category and used as a reference for comparison against responses 226 
of “Less active”. 227 
 228 
Results: 229 
Using COPD status as a predictor of the walking abnormalities without covariates, it was found 230 
that each COPD classification compared against normal were significantly (p < 0.05) associated 231 
to walking abnormalities. Upon adding the covariates into the model, SEVERE COPD (odds 232 
ratio: 2.53, 95% CI: 1.2 to 5.3) remained significantly (p = 0.01) associated to walking 233 
abnormalities. The covariates of age (odds ratio: 1.10, 95% CI: 1.1 to 1.1) and BMI (odds ratio: 234 
1.06, 95% CI: 1.0 to 1.1) were also significantly (p < 0.0001) associated to walking 235 
abnormalities. These results are presented in Table 3 and 4. 236 
 237 
Furthermore, we found that SEVERE (odds ratio: 4.57, 95% CI: 2.6 to 7.9), MODERATE (odds 238 
ratio: 1.83, 95% CI: 1.3 to 2.5), SYMPTOMS (odds ratio: 1.84, 95% CI: 1.5 to 2.3), 239 
RESTRICTIVE (odds ratio: 2.43, 95% CI: 1.9 to 3.1), BMI (odds ratio: 1.0, 95% CI: 1.0 to 1.1), 240 
and current smoker (odds ratio: 1.4, 95% CI: 1.2 to 1.8) were significantly (p < 0.05) associated 241 
with less activity than other men/women their age. Age (odds ratio: 0.97, 95% CI: 0.96 to 0.98) 242 
was significantly (p < 0.0001) associated with the response of more active or about the same 243 
compared to other men/women their age. These results are presented in Table 5. 244 
 245 
Discussion: 246 
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The purpose of this study was to investigate whether or not walking abnormalities are associated 247 
with the presence of COPD using data from the NHANES III dataset. It was hypothesized that 248 
walking abnormalities would be significantly associated with COPD severity, due to the 249 
prevalence of peripheral dysfunction due to decrease physical activity levels noted in COPD. The 250 
novel finding is that COPD is related to walking abnormalities. When using a comprehensive 251 
classification scheme for COPD status, a significant association between severe COPD status 252 
and walking abnormalities was observed. From clinical point of view, reduced physical activity 253 
in daily life and impaired muscle strength are the mostly likely causes. This was confirmed as 254 
demonstrated by decreased physical activity being significantly associated will all levels of 255 
COPD severity. These results strengthen the novel findings by demonstrating the importance of 256 
physical activity and the effect of inactivity on walking abnormalities. Thus, questions are raised 257 
as to why persons with severe COPD would suffer from walking abnormalities and how is this 258 
clinically relevant? 259 
 260 
One potential explanation for the association between walking abnormalities and COPD severity 261 
could be the result of decreased physical activity. It has been shown that decreased levels of 262 
physical activity result in decreased muscle fiber cross-sectional area, reduction in mitochondrial 263 
density, capillary density, and amount of contractile proteins, and increased susceptibility to 264 
assuming properties of type II fibers 43. Skeletal muscle dysfunction present in COPD includes 265 
loss of body cell mass and protein degradation, impaired energy production and metabolic 266 
performance, increased susceptibility to leg fatigue, and leg weakness leading to reduced activity  267 
2, 6-8, 14, 15, 26-32. These dysfunctions in the muscular system may impact walking patterns, causing an 268 
irregular walking pattern, and further causing decreased levels of physical activity. Mechanisms 269 
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leading to reduced physical activity levels of COPD patients have been debated, though it has 270 
been demonstrated that activity may be limited in COPD patients due to peripheral muscle 271 
fatigue 24. Recently, using surface electromyography COPD patients demonstrated muscle 272 
contractile fatigue in the rectus femoris and vastus lateralis during a 6 minute walk test of COPD 273 
patients 44. There is a growing body of evidence that peripheral muscle fatigue is associated to 274 
structural and mechanical abnormalities of skeletal muscle in COPD patients. For instance, it has 275 
been documented that skeletal muscle contractile fatigue is affected by metabolic changes in the 276 
skeletal muscle, redox status, systemic inflammation, and lactic acid accumulation 45-48.  It is 277 
possible that fatigue is the result of mitochondrial changes in COPD skeletal muscle that are 278 
related to a greater presence of type II muscle fibers 4, 49. It has been demonstrated that sedentary 279 
controls also demonstrate a profile of increased number of type II muscle fibers 50; therefore, it is 280 
possible disuse may be the mechanism for mitochondrial changes in COPD patients leading to 281 
further decrements in activity levels. This is further strengthened by studies that have 282 
demonstrated that limitation in mechanical efficiency and  submaximal exercise is related to an 283 
increased percentage of type II fibers and muscle disuse as opposed to peripheral muscle 284 
oxygenation, respectively 51, 52. Further, studies have demonstrated positive effects of exercise 285 
training on COPD patients 53-57. These positive effects include increased muscular size, strength, 286 
power, endurance, mitochondrial capacity, and restoration of protein levels 58-61. 287 
 288 
Alternatively, systemic inflammation in organ systems outside of the lungs, distinct from local 289 
pulmonary inflammation may potentially be another mechanism to walking abnormalities in 290 
COPD. This inflammation, characterized by oxidative stress, increased levels of cytokines and 291 
leukocytes, has been speculated as an underlying mechanism of abnormal skeletal muscle 292 
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structure and function in COPD 2, 3, 5, 45-47. Whether the abnormalities in gait in COPD patients 293 
demonstrated in the present study result from inactivity or from other processes remains to be 294 
determined. 295 
 296 
There are limitations associated with this study. NHANES III dataset allows for limited 297 
investigations into the association of COPD and walking abnormalities. Walking abnormalities 298 
in this dataset are poorly defined and include overall observations of walking patterns, such as 299 
the presence of a limp or shuffle. Future studies should investigate mechanical abnormalities 300 
using a biomechanical analysis in order to thoroughly understand the muscular joint responses 301 
and contributions to walking patterns. In addition, the variable used to define physical activity 302 
levels was subjectively provided. Subjects were asked their opinion on their activity level as 303 
compared to other adults their same age. Use of accelerometers and pedometers provide 304 
objective measures of physical activity 10-13.  305 
 306 
This analysis of the NHANES III dataset is the first study that investigated whether or not 307 
walking abnormalities are associated with COPD status. The novel finding of this study is that 308 
COPD is related to gait abnormalities. From clinical point of view, reduced physical activity in 309 
daily life and impaired muscle strength are the mostly likely causes. There has been much debate 310 
in the literature as to the peripheral effects of COPD and whether or not mechanical outcomes 311 
are associated with severity of the disease. Further studies should employ objective analyses to 312 
investigate mechanical outcomes of COPD patients to determine these associations. The 313 
biomechanical analysis of walking abnormalities would provide procedures and measures that 314 
can clearly examine the locomotion of COPD patients by identifying physical deficiencies and 315 
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determining the severity of their mechanical limitations.  In conclusion, this study provides 316 
preliminary evidence that a decline in mechanical outcomes (e.g. walking abnormalities) is 317 
associated with persons that have severe COPD. 318 
 319 
Acknowledgements: 320 
This work was supported by the Nebraska NASA Space Grant & EPSCoR Fellowship, the 321 
University of Nebraska Medical Center, Center for Clinical and Translational Research Pilot 322 
Grant Program, and the Nebraska Research Initiative. The funding sources had no involvement 323 
in the design, collection, or interpretation of data or writing of the manuscript. 324 
  325 
Page 16 
 
References  326 
1. Fabbri LM and Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 327 
2007; 370: 797-799.  328 
2. Gosker HR, van Mameren H, van Dijk PJ, Engelen MPKJ, van der Vusse GJ, Wouters EFM 329 
and Schols AMWJ. Skeletal muscle fibre-type shifting and metabolic profile in patients with 330 
chronic obstructive pulmonary disease. Eur.Respir.J. 2002; 19: 617-625.  331 
3. Gosker HR, Hesselink MK, Duimel H, Ward KA and Schols AM. Reduced mitochondrial 332 
density in the vastus lateralis muscle of patients with COPD. Eur.Respir.J. 2007; 30: 73-79.  333 
4. Picard M, Godin R, Sinnreich M, Baril J, Bourbeau J, Perrault H, Taivassalo T and Burelle Y. 334 
The mitochondrial phenotype of peripheral muscle in chronic obstructive pulmonary disease: 335 
disuse or dysfunction? Am.J.Respir.Crit.Care Med. 2008; 178: 1040-1047.  336 
5. Puente-Maestu L, Pérez-Parra J, Godoy R, Moreno N, Tejedor A, González-Aragoneses F, 337 
Bravo JL, Alvarez FV, Camaño S and Agustí A. Abnormal mitochondrial function in locomotor 338 
and respiratory muscles of COPD patients. Eur.Respir.J. 2009; 33: 1045-1052.  339 
6. Pitta F, Troosters T, Probst VS, Spruit MA, Decramer M and Gosselink R. Physical activity 340 
and hospitalization for exacerbation of COPD. Chest 2006; 129: 536-544.  341 
7. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M and Gosselink R. Characteristics of 342 
physical activities in daily life in chronic obstructive pulmonary disease. Am.J.Respir.Crit.Care 343 
Med. 2005; 171: 972-977.  344 
8. Garcia-Aymerich J, Félez MA, Escarrabill J, Marrades RM, Morera J, Elosua R and Antó JM. 345 
Physical activity and its determinants in severe chronic obstructive pulmonary disease. 346 
Med.Sci.Sports Exerc. 2004; 36: 1667-1673.  347 
Page 17 
 
9. Hernandes NA, Teixeira DdC, Probst VS, Brunetto AF, Ramos EMC and Pitta F. Profile of 348 
the level of physical activity in the daily lives of patients with COPD in Brazil. J Bras Pneumol 349 
2009; 35: 949-956.  350 
10. Steele BG, Holt L, Belza B, Ferris S, Lakshminaryan S and Buchner DM. Quantitating 351 
physical activity in COPD using a triaxial accelerometer. Chest 2000; 117: 1359-1367.  352 
11. Hecht A, Ma S, Porszasz J, Casaburi R and COPD Clinical Research Network. Methodology 353 
for using long-term accelerometry monitoring to describe daily activity patterns in COPD. 354 
COPD 2009; 6: 121-129.  355 
12. Moy ML, Matthess K, Stolzmann K, Reilly J and Garshick E. Free-living physical activity in 356 
COPD: assessment with accelerometer and activity checklist. J.Rehabil.Res.Dev. 2009; 46: 277-357 
286.  358 
13. Moy ML, Garshick E, Matthess KR, Lew R and Reilly JJ. Accuracy of uniaxial 359 
accelerometer in chronic obstructive pulmonary disease. J.Rehabil.Res.Dev. 2008; 45: 611-617.  360 
14. Cohen MD and Cutaia M. A novel approach to measuring activity in chronic obstructive 361 
pulmonary disease: using 2 activity monitors to classify daily activity. 362 
J.Cardiopulm.Rehabil.Prev. 2010; 30: 186-194.  363 
15. Watz H, Waschki B, Meyer T and Magnussen H. Physical activity in patients with COPD. 364 
Eur.Respir.J. 2009; 33: 262-272.  365 
16. O'Donnell DE and Laveneziana P. The clinical importance of dynamic lung hyperinflation in 366 
COPD. COPD 2006; 3: 219-232.  367 
17. Garcia-Rio F, Lores V, Mediano O, Rojo B, Hernanz A, López-Collazo E and Alvarez-Sala 368 
R. Daily physical activity in patients with chronic obstructive pulmonary disease is mainly 369 
associated with dynamic hyperinflation. Am.J.Respir.Crit.Care Med. 2009; 180: 506-512.  370 
Page 18 
 
18. MacIntyre N. Mechanisms of functional loss in patients with chronic lung disease. 371 
Respir.Care 2008; 53: 1177-1184.  372 
19. Watz H, Waschki B, Boehme C, Claussen M, Meyer T and Magnussen H. Extrapulmonary 373 
effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. 374 
Am.J.Respir.Crit.Care Med. 2008; 177: 743-751.  375 
20. Aboudrar S, Desplanches D, Graber-von Bergen F, Favier R, Okyayuz-Baklouti I and 376 
Hoppeler H. Effects of torbafylline on muscle atrophy: prevention and recovery. 377 
Can.J.Physiol.Pharmacol. 1992; 70: 814-820.  378 
21. Fitts RH, Riley DR and Widrick JJ. Functional and structural adaptations of skeletal muscle 379 
to microgravity. J.Exp.Biol. 2001; 204: 3201-3208.  380 
22. Riley DA, Bain JL, Thompson JL, Fitts RH, Widrick JJ, Trappe SW, Trappe TA and Costill 381 
DL. Disproportionate loss of thin filaments in human soleus muscle after 17-day bed rest. 382 
Muscle Nerve 1998; 21: 1280-1289.  383 
23. Tyml K and Mathieu-Costello O. Structural and functional changes in the microvasculature 384 
of disused skeletal muscle. Front.Biosci. 2001; 6: D45-52.  385 
24. Saey D, Debigare R, LeBlanc P, Mador MJ, Cote CH, Jobin J and Maltais F. Contractile leg 386 
fatigue after cycle exercise: a factor limiting exercise in patients with chronic obstructive 387 
pulmonary disease. Am.J.Respir.Crit.Care Med. 2003; 168: 425-430.  388 
25. Coronell C, Orozco-Levi M, Méndez R, Ramírez-Sarmiento A, Gáldiz JB and Gea J. 389 
Relevance of assessing quadriceps endurance in patients with COPD. Eur.Respir.J. 2004; 24: 390 
129-136.  391 
Page 19 
 
26. Anonymous Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A 392 
statement of the American Thoracic Society and European Respiratory Society. 393 
Am.J.Respir.Crit.Care Med. 1999; 159: S1-40.  394 
27. Allaire J, Maltais F, Doyon J, Noël M, LeBlanc P, Carrier G, Simard C and Jobin J. 395 
Peripheral muscle endurance and the oxidative profile of the quadriceps in patients with COPD. 396 
Thorax 2004; 59: 673-678.  397 
28. Bernard S, LeBlanc P, Whittom F, Carrier G, Jobin J, Belleau R and Maltais F. Peripheral 398 
muscle weakness in patients with chronic obstructive pulmonary disease. Am.J.Respir.Crit.Care 399 
Med. 1998; 158: 629-634.  400 
29. Hamilton AL, Killian KJ, Summers E and Jones NL. Muscle strength, symptom intensity, 401 
and exercise capacity in patients with cardiorespiratory disorders. Am.J.Respir.Crit.Care Med. 402 
1995; 152: 2021-2031.  403 
30. Hamilton AL, Killian KJ, Summers E and Jones NL. Symptom intensity and subjective 404 
limitation to exercise in patients with cardiorespiratory disorders. Chest 1996; 110: 1255-1263.  405 
31. Mador MJ, Deniz O, Aggarwal A and Kufel TJ. Quadriceps fatigability after single muscle 406 
exercise in patients with chronic obstructive pulmonary disease. Am.J.Respir.Crit.Care Med. 407 
2003; 168: 102-108.  408 
32. Maltais F, LeBlanc P, Whittom F, Simard C, Marquis K, Bélanger M, Breton MJ and Jobin J. 409 
Oxidative enzyme activities of the vastus lateralis muscle and the functional status in patients 410 
with COPD. Thorax 2000; 55: 848-853.  411 
33. Wouters EFM, Creutzberg EC and Schols AMWJ. Systemic effects in COPD. Chest 2002; 412 
121: 127S-130s.  413 
Page 20 
 
34. Butcher SJ, Meshke JM and Sheppard MS. Reductions in functional balance, coordination, 414 
and mobility measures among patients with stable chronic obstructive pulmonary disease. 415 
J.Cardiopulm.Rehabil. 2004; 24: 274-280.  416 
35. Smith MD, Chang AT, Seale HE, Walsh JR and Hodges PW. Balance is impaired in people 417 
with chronic obstructive pulmonary disease. Gait Posture 2010; 31: 456-460.  418 
36. Beauchamp MK, Hill K, Goldstein RS, Janaudis-Ferreira T and Brooks D. Impairments in 419 
balance discriminate fallers from non-fallers in COPD. Respir.Med. 2009; 103: 1885-1891.  420 
37. Hellstrom K, Vahlberg B, Urell C and Emtner M. Fear of falling, fall-related self-efficacy, 421 
anxiety and depression in individuals with chronic obstructive pulmonary disease. Clin.Rehabil. 422 
2009; 23: 1136-1144.  423 
38. Roig M, Eng JJ, Road JD and Reid WD. Falls in patients with chronic obstructive pulmonary 424 
disease: a call for further research. Respir.Med. 2009; 103: 1257-1269.  425 
39. Anonymous The definition of emphysema. Report of a National Heart, Lung, and Blood 426 
Institute, Division of Lung Diseases workshop. Am.Rev.Respir.Dis. 1985; 132: 182-185.  427 
40. Hankinson JL, Odencrantz JR and Fedan KB. Spirometric reference values from a sample of 428 
the general U.S. population. Am.J.Respir.Crit.Care Med. 1999; 159: 179-187.  429 
41. Fabbri L, Pauwels RA and Hurd SS. Global Strategy for the Diagnosis, Management, and 430 
Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary updated 431 
2003. COPD 2004; 1: 105-141.  432 
42. Mannino DM, Buist AS, Petty TL, Enright PL and Redd SC. Lung function and mortality in 433 
the United States: data from the First National Health and Nutrition Examination Survey follow 434 
up study. Thorax 2003; 58: 388-393.  435 
Page 21 
 
43. Boonyarom O and Inui K. Atrophy and hypertrophy of skeletal muscles: structural and 436 
functional aspects. Acta Physiol (Oxf) 2006; 188: 77-89.  437 
44. Marquis N, Debigaré R, Bouyer L, Saey D, Laviolette L, Brouillard C and Maltais F. 438 
Physiology of Walking in Patients with Moderate to Severe Chronic Obstructive Pulmonary 439 
Disease. Med.Sci.Sports Exerc. 2009; 41: 1540-1548.  440 
45. Sahlin K. Metabolic factors in fatigue. Sports Med. 1992; 13: 99-107.  441 
46. Sahlin K. Muscle fatigue and lactic acid accumulation. Acta Physiol.Scand.Suppl. 1986; 556: 442 
83-91.  443 
47. Sahlin K, Katz A and Henriksson J. Redox state and lactate accumulation in human skeletal 444 
muscle during dynamic exercise. Biochem.J. 1987; 245: 551-556.  445 
48. Smith MA and Reid MB. Redox modulation of contractile function in respiratory and limb 446 
skeletal muscle. Respir Physiol Neurobiol 2006; 151: 229-241.  447 
49. Satta A, Migliori GB, Spanevello A, Neri M, Bottinelli R, Canepari M, Pellegrino MA and 448 
Reggiani C. Fibre types in skeletal muscles of chronic obstructive pulmonary disease patients 449 
related to respiratory function and exercise tolerance. Eur.Respir.J. 1997; 10: 2853-2860.  450 
50. Larsson L and Ansved T. Effects of long-term physical training and detraining on enzyme 451 
histochemical and functional skeletal muscle characteristic in man. Muscle Nerve 1985; 8: 714-452 
722.  453 
51. Austin KG, Mengelkoch L, Hansen J, Shahady E, Sirithienthad P and Panton L. Comparison 454 
of oxygenation in peripheral muscle during submaximal aerobic exercise, in persons with COPD 455 
and healthy, matched-control persons. Int J Chron Obstruct Pulmon Dis 2006; 1: 467-475.  456 
52. Richardson RS, Leek BT, Gavin TP, Haseler LJ, Mudaliar SRD, Henry R, Mathieu-Costello 457 
O and Wagner PD. Reduced mechanical efficiency in chronic obstructive pulmonary disease but 458 
Page 22 
 
normal peak VO2 with small muscle mass exercise. Am J Respir Crit Care Med 2004; 169: 89-459 
96.  460 
53. Ortega F, Toral J, Cejudo P, Villagomez R, Sánchez H, Castillo J and Montemayor T. 461 
Comparison of effects of strength and endurance training in patients with chronic obstructive 462 
pulmonary disease. Am.J.Respir.Crit.Care Med. 2002; 166: 669-674.  463 
54. Bernard S, Whittom F, Leblanc P, Jobin J, Belleau R, Bérubé C, Carrier G and Maltais F. 464 
Aerobic and strength training in patients with chronic obstructive pulmonary disease. 465 
Am.J.Respir.Crit.Care Med. 1999; 159: 896-901.  466 
55. Borghi-Silva A, Oliveira CC, Carrascosa C, Maia J, Berton DC, Queiroga F, J., Ferreira EM, 467 
Almeida DR, Nery LE and Neder JA. Respiratory muscle unloading improves leg muscle 468 
oxygenation during exercise in patients with COPD. Thorax 2008; 63: 910-915.  469 
56. Lewis MI, Fournier M, Storer TW, Bhasin S, Porszasz J, Ren S, Da X and Casaburi R. 470 
Skeletal muscle adaptations to testosterone and resistance training in men with COPD. 471 
J.Appl.Physiol. 2007; 103: 1299-1310.  472 
57. Varga J, Porszasz J, Boda K, Casaburi R and Somfay A. Supervised high intensity 473 
continuous and interval training vs. self-paced training in COPD. Respir.Med. 2007; 101: 2297-474 
2304.  475 
58. Kongsgaard M, Backer V, Jørgensen K, Kjaer M and Beyer N. Heavy resistance training 476 
increases muscle size, strength and physical function in elderly male COPD-patients--a pilot 477 
study. Respir.Med. 2004; 98: 1000-1007.  478 
59. McKeough ZJ, Alison JA, Bye PT, Trenell MI, Sachinwalla T, Thompson CH and Kemp GJ. 479 
Exercise capacity and quadriceps muscle metabolism following training in subjects with COPD. 480 
Respir.Med. 2006; 100: 1817-1825.  481 
Page 23 
 
60. Franssen FME, Broekhuizen R, Janssen PP, Wouters EFM and Schols AMWJ. Limb muscle 482 
dysfunction in COPD: effects of muscle wasting and exercise training. Med.Sci.Sports Exerc. 483 
2005; 37: 2-9.  484 
61. Gosker HR, Schrauwen P, Broekhuizen R, Hesselink MKC, Moonen-Kornips E, Ward KA, 485 
Franssen FME, Wouters EFM and Schols AMWJ. Exercise training restores uncoupling protein-486 
3 content in limb muscles of patients with chronic obstructive pulmonary disease. 487 
Am.J.Physiol.Endocrinol.Metab. 2006; 290: E976-E981.  488 
 489 
  490 
Page 24 
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Table 1. Classification of subjects based upon GOLD standards.42 492 
 493 
Table 2.  Descriptive Statistics for Continuous and Categorical Variables. 494 
 495 
Table 3.  Logistic Regression of Walking Abnormalities by COPD Status.  N=8,405 496 
(84,234,791) 497 
1. Reference category is Normal. 498 
 499 
Table 4. Logistic Regression of Walking Abnormalities by COPD Status, Age, BMI, Sex, and 500 
Smoking Status.  N=8,389 (84,146,857) (Note: * indicates p < 0.05) 501 
1. Reference category is Normal. 502 
2. Reference category is Never Smoked. 503 
 504 
Table 5. Logistic Regression of Physical Activity compared to men/women of comparable age 505 
by COPD Status, Age, BMI, Sex, and Smoking Status.  N=8,193 (82,225,630) (Note: * indicates 506 
p < 0.05) 507 
1. Reference category is Normal. 508 
2. Reference category is Never Smoked. 509 
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